As part of the new collaboration, the two companies will work together to co-create the candidate for the oncology target, leveraging PepMetics technology.  Once the development candidate is The post PRISM, ONO to co-create development candidate for oncology target appeared first on Pharmaceutical Business review.

This acceptance will allow GSK to potentially expand the use of Jemperli for the treatment of primary advanced or recurrent endometrial cancer in all the adult patients, including The post US FDA accepts sBLA for GSK’s Jemperli for broader endometrial cancer use appeared first on Pharmaceutical Business review.

As part of this strategic partnership, the two companies aim to leverage their shared technology as well as clinical development resources to create synergies in therapeutics development.  The The post OSR Holdings, SillaJen sign MoU to pursue drug development appeared first on Pharmaceutical Business review.

The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS The post BMS to boost CAR T cell therapy production with Cellares deal appeared first on Pharmaceutical Business review.

Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in The post Merck’s PREVYMIS gets Health Canada’s approval for CMV disease prevention appeared first on Pharmaceutical Business review.

This partnership follows the US Food and Drug Administration’s approval of ADSTILADRIN in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) The post SK pharmteco signs agreement to manufacture Ferring’s ADSTILADRIN appeared first on Pharmaceutical Business review.